## Abstract ## Background and Objective Photodynamic therapy (PDT) is FDA‐approved anti‐cancer modality for elimination of early disease and palliation in advanced disease. PDT efficacy depends in part on elicitation of a tumor‐specific immune response that is dependent on cytotoxic T lymphocytes
A novel MHC class I-related molecule expressed on mouse thymic stroma cells and mature lymphocytes
✍ Scribed by Keiko Mori; Kazuho Hirata; Masaru Kawabuchi; Manabu Nakashima; Takeshi Watanabe
- Publisher
- Springer-Verlag
- Year
- 1991
- Tongue
- English
- Weight
- 651 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0093-7711
No coin nor oath required. For personal study only.
✦ Synopsis
A monoclonal antibody (mAb) TP-3 has been established by immunizing rats with the BALB/c mouse thymic epithelial cell line TEL-2. The TP-3 antigen is expressed on stroma cells of thymus, spleen, and lymph node in syngeneic BALB/c mice (H-2d). This antigen is also expressed at a low level on the cell surface of immature thymocytes, and at a high level on mature T and B cells. In allogeneic mice such as C57BL/6 (H-2b) or C3H (H-2k), no cells expressed the TP-3 antigen. Using H-2 congenic mice, reactivity with mAb TP-3 was found to map to a region of H-2DdLd or between Dd and Qa, suggesting that TP-3 is a major histocompatibility complex (MHC) class I antigen. However, immunoprecipitation analysis indicated that this antigen is not identical to the classical mouse class I molecules in terms of molecular size, antigenicity, and tissue distribution.
📜 SIMILAR VOLUMES